

# Iakovos Toumazis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4053314/publications.pdf>

Version: 2024-02-01

18  
papers

833  
citations

759233

12  
h-index

888059

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

706  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. JAMA - Journal of the American Medical Association, 2021, 325, 988.	7.4	181
2	Risk-Based lung cancer screening: A systematic review. Lung Cancer, 2020, 147, 154-186.	2.0	136
3	Routing hazardous materials on time-dependent networks using conditional value-at-risk. Transportation Research Part C: Emerging Technologies, 2013, 37, 73-92.	7.6	84
4	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine, 2019, 171, 796.	3.9	81
5	Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results. JAMA Network Open, 2019, 2, e190204.	5.9	70
6	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. Journal of the National Cancer Institute, 2020, 112, 466-479.	6.3	67
7	Disparities of National Lung Cancer Screening Guidelines in the US Population. Journal of the National Cancer Institute, 2020, 112, 1136-1142.	6.3	48
8	Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes and Control, 2017, 28, 947-958.	1.8	38
9	Worst-Case Conditional Value-at-Risk Minimization for Hazardous Materials Transportation. Transportation Science, 2016, 50, 1174-1187.	4.4	33
10	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncology, 2021, 7, 1833.	7.1	29
11	Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings. JNCI Cancer Spectrum, 2019, 3, pkz035.	2.9	22
12	Value-at-Risk and Conditional Value-at-Risk Minimization for Hazardous Materials Routing. Profiles in Operations Research, 2013, , 127-154.	0.4	15
13	A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker. JNCI Cancer Spectrum, 2021, 5, pkab081.	2.9	10
14	Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecologic Oncology, 2021, 161, 56-62.	1.4	7
15	A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. Cancer, 2021, 127, 4432-4446.	4.1	7
16	Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy and Practice, 2017, 2, 238146831772965.	0.9	3
17	Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening. Journal of the American College of Radiology, 2021, 18, 1614-1623.	1.8	2
18	P1.11-03 Disparities and National Lung Cancer Screening Guidelines in the U.S. Population. Journal of Thoracic Oncology, 2019, 14, S515-S516.	1.1	0